Prenetics Global Raises IM8 Revenue Guidance, Reports Strong Q1 Growth & $19M Buyback
PRE has more than doubled off its 52-week low of $5.1.
Summary
Prenetics Global announced preliminary Q1 2026 results with strong IM8 revenue growth and raised full-year guidance, alongside the execution of a significant portion of its share buyback program.
Key Events · Earnings and Guidance · PRE
-
Raised Full-Year IM8 Revenue Guidance
The company increased its full-year 2026 IM8 revenue guidance to $190 million-$210 million, up from the previous range of $180 million-$200 million, reflecting strong brand momentum.
-
Strong Q1 2026 Performance
Prenetics reported preliminary Q1 2026 revenue of $36.0 million, with its IM8 brand revenue growing nearly 6x year-over-year to $33.8 million and 23.1% sequentially from Q4 2025.
-
Significant Share Repurchase Execution
The company repurchased approximately $19 million of its Class A Ordinary Shares through May 13, 2026, representing nearly half of the authorized $40 million share buyback program.
-
Robust Cash Position
Prenetics maintained a strong, debt-free balance sheet with approximately $147 million in combined estimated cash balances, current financial assets, and cash consideration held in escrow as of May 13, 2026.
Analysis · PRE · Industrial Applications And Services
Prenetics Global reported preliminary Q1 2026 results showing significant growth in its IM8 brand, which saw nearly 6x year-over-year revenue increase and 23.1% sequential growth. The company raised its full-year IM8 revenue guidance to $190M-$210M and executed $19 million of its share repurchase program, demonstrating strong financial health and confidence in its strategic shift to consumer health.
At the time of this filing, PRE was trading at $17.63 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $295.7M. The 52-week trading range was $5.10 to $23.63. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.